IPFIPF-PPCNCT06714188
Application of Personalized Palliative Care in Patients With Newly Diagnosed Idiopathic Pulmonary Fibrosis
An observational study of IPF, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 1 site in Italy.
Trial summary
This study aims to develop a tool that helps the medical-nursing team in the identification of the real palliative care needs of each individual patient. Patients with newly diagnosed Idiopathic Pulmonary Fibrosis will be asked just a few simple questions in order to place them at the most appropriate level of… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- IPF
- How many people
- 30 participants
- Where
- 1 siteItaly
- Study dates
- 19 Sep 2023to 30 Jun 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) established after discussion at the Multidisciplinary Interstitial Disease Meeting and referred to the APPI Fibrosi unit of the IRCCS for specialized care
Who may be able to join
- Age ≥ 18 years.
- New diagnosis of Idiopathic Pulmonary Fibrosis (IPF) established through a Multidisciplinary Interstitial Disease Meeting.
- Obtaining written informed consent.
Who cannot join
- Patient's inability to understand and/or respond to the questions in the questionnaire as judged by the healthcare provider.
- Patient already receiving care from the Palliative Care Service.
Trial locations and contacts
1 site in 1 country.
Italy1 site
IRCCS Azienda Ospedaliera-Universitaria di Bologna
Bologna, Bologna, 40138
About this study
Official title: Application of Personalized Palliative Care in Patients With Newly Diagnosed Idiopathic Pulmonary Fibrosis - An Exploratory-Descriptive Study
This study aims to develop a tool that helps the medical-nursing team in the identification of the real palliative care needs of each individual patient. Patients with newly diagnosed Idiopathic Pulmonary Fibrosis will be asked just a few simple questions in order to place them at the most appropriate level of palliative care (PC) even before the first medical contact. This would not only optimize resource allocation (e.g., allowing patients with low palliative needs to be assessed solely by the PC nurse), but also benefit patients who have difficulty leaving their homes by enabling them to receive evaluation and palliative care directly at home rather than after a hospital assessment.
Read the detailed description
The population of this study consists of patients with newly diagnosed Idiopathic Pulmonary Fibrosis (IPF) who are being followed at the specialized outpatient clinics of APPI Fibrosi, within the Unit of Pulmonology and Respiratory Intensive Care, at the IRCCS Azienda Ospedaliero-Universitaria, Policlinico di S. Orsola.
During the initial interview prior to the pulmonology visit, Pulmonologist A will inform the patient about the study, provide the information sheet, and obtain informed consent for participation in the study and data processing. Subsequently, the questionnaire will be used to interview the patients, collect their responses, and assign them to the corresponding level of palliative care (PC) according to the score obtained. The assignment to the level of PC intensity made by Pulmonologist A will not in any way modify the patient's allocation to the level of PC.
During the pulmonology visit, which takes place immediately after the questionnaire administration, Pulmonologist B will conduct the visit according to the standard procedures (collection of past medical history, recent history, occupational history, family history, evaluation of laboratory and instrumental tests, medical examination, measurement of viral parameters, potential prescription of antifibrotic medication, and oxygen therapy if respiratory failure is detected, etc.). At the end of the visit, Pulmonologist B will give their clinical judgment on the appropriate level of PC required for the patient, based on the visit and collected data.
On the same day, the patient will also have an appointment with the PC team (doctor and nurse), as per current protocols at APPI Fibrosi IRCCS AOUBO, during which information on the patient's symptoms, the impact of symptoms on daily life activities, quality of life (QoL), and the patient's support network will be gathered. At the end of the visit, the PC team will express their judgment on the referral of a patient to a specific level of PC, based on the visit and collected data.
As per clinical practice, Pulmonologist B can give their own opinion, but the final decision regarding the assignment is made by the PC team.
The questions administered through the questionnaire were formulated based on elements identified during the clinical practice of pulmonologists and the dedicated nurse of the APPI Fibrosi unit at the IRCCS. These elements are considered most likely to be associated with the need for a higher level of palliative care (PC), namely:
Use of oxygen therapy: This implies the presence of underlying organ failure (respiratory failure) and often constitutes an obstacle for patients leaving their homes, either due to induced depressive and/or anxious states or due to difficulties-especially among elderly patients-in using oxygen therapy devices. IPF is a disease often complicated by the development of chronic partial respiratory failure. Patients are thus at risk of chronic hypoxia and receive long-term home oxygen therapy prescriptions. Although there is no specific literature on adherence to chronic oxygen therapy in IPF patients, it can be assumed to be similar to that observed in patients with other chronic respiratory diseases. In a cohort of patients with chronic obstructive pulmonary disease (COPD), overall adherence to oxygen therapy was 60%, dropping further among those prescribed 24-hour therapy. An Italian study on COPD patients found that only 40% used portable oxygen devices to leave their homes, citing "shame" as the primary limiting factor. Investigators believe that many IPF patients similarly restrict their outings for the same reason.
Progressive exertional dyspnea: This is a common symptom in IPF patients, impacting their quality of life (QoL) over months and years. As the disease progresses, worsening dyspnea makes even minimal physical activities difficult, affecting various aspects of life, including family relationships and social participation. Therefore, investigators have decided to assign a higher score to patients with greater dyspnea levels, as measured by the modified Medical Research Council (mMRC) scale. The mMRC scale is structured as follows:
mMRC 0: Dyspnea with strenuous exertion. mMRC 1: Dyspnea with moderate-to-intense exertion (e.g., brisk walking or running on level ground or slight incline).
mMRC 2: Dyspnea with moderate exertion (e.g., slower walking on level ground compared to peers or needing to stop during normal-paced walking).
mMRC 3: Dyspnea with light exertion (e.g., needing to stop to breathe after walking 100 meters or for a few minutes on level ground).
mMRC 4: Dyspnea at rest (e.g., experiencing dyspnea while dressing or undressing).
Difficulties in reaching the center (APPI Fibrosi) for logistical reasons or lack of caregiver support: Patients with such difficulties are more likely to refuse palliative care at the IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di S. Orsola, which puts them at risk of not receiving adequate support for managing symptoms associated with their underlying condition. On the other hand, home-based or community-based care presents an opportunity for those who would otherwise face challenges in accessing care.
- Conditions
- IPF
- Keywords
- Questionnaire, Palliative Care, IPF
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluation of concordance between the levels of palliative care obtained using a triage questionnaire and those derived from the clinical judgments of the dedicated pulmonologist and the dedicated palliative care physician
The primary objective will be measured by calculating Krippendorff's alpha coefficient of reliability among the classifications obtained with the questionnaire, the clinical judgment of the pulmonologist, and the clinical judgment of the palliative care physician
Measured: 18 months
Secondary outcomes (1)
Description of the degree of palliative care needs that patients with IPF present when referred to the reference pulmonology center
The secondary objective will be measured by calculating the percentage of patients assigned to each level of palliative care (PC) by the questionnaire, the pulmonologist, and the palliative care physician, as well as the number of patients who, at the time of formal IPF diagnosis, require a high level of palliative care according to the judgment of the pulmonologist and the palliative care team
Measured: 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Dec 2024
- Study start19 Sep 2023
- Primary completion17 Jul 2024
- Study completion30 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for IPFStudies of the same condition, open and under way.
- More trials run by IRCCS Azienda Ospedaliero-Universitaria di BolognaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Stefano Nava, MD, Principal investigator, IRCCS Azienda Ospedaliero-Universitaria di Bologna
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06714188
- Sponsor's protocol ID
- IPF-PPC
- Acronym
- IPF-PPC
- Status last verified
- Jan 2026
- First submitted
- 28 Nov 2024
- Last updated
- 2 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 2 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Application of Personalized Palliative Care in Patients With Newly Diagnosed Idiopathic Pulmonary Fibrosis - An Exploratory-Descriptive Study
- ClinicalTrials.gov ID
- NCT06714188
- Acronym / sponsor ID
- IPF-PPC / IPF-PPC
- Conditions
- IPF
- Keywords
- Questionnaire, Palliative Care, IPF
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- IRCCS Azienda Ospedaliero-Universitaria di BolognaUniversity, hospital or other
- Study start
- 19 Sep 2023 (actual)
- Primary completion
- 17 Jul 2024 (actual)
- Study completion
- 30 Jun 2025 (actual)
- First posted
- 3 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to develop a tool that helps the medical-nursing team in the identification of the real palliative care needs of each individual patient. Patients with newly diagnosed Idiopathic Pulmonary Fibrosis will be asked just a few simple questions in order to place them at the most appropriate level of palliative care (PC) even before the first medical contact. This would not only optimize resource allocation (e.g., allowing patients with low palliative needs to be assessed solely by the PC nurse), but also benefit patients who have difficulty leaving their homes by enabling them to receive evaluation and palliative care directly at home rather than after a hospital assessment.
Detailed description
The population of this study consists of patients with newly diagnosed Idiopathic Pulmonary Fibrosis (IPF) who are being followed at the specialized outpatient clinics of APPI Fibrosi, within the Unit of Pulmonology and Respiratory Intensive Care, at the IRCCS Azienda Ospedaliero-Universitaria, Policlinico di S. Orsola.
During the initial interview prior to the pulmonology visit, Pulmonologist A will inform the patient about the study, provide the information sheet, and obtain informed consent for participation in the study and data processing. Subsequently, the questionnaire will be used to interview the patients, collect their responses, and assign them to the corresponding level of palliative care (PC) according to the score obtained. The assignment to the level of PC intensity made by Pulmonologist A will not in any way modify the patient's allocation to the level of PC.
During the pulmonology visit, which takes place immediately after the questionnaire administration, Pulmonologist B will conduct the visit according to the standard procedures (collection of past medical history, recent history, occupational history, family history, evaluation of laboratory and instrumental tests, medical examination, measurement of viral parameters, potential prescription of antifibrotic medication, and oxygen therapy if respiratory failure is detected, etc.). At the end of the visit, Pulmonologist B will give their clinical judgment on the appropriate level of PC required for the patient, based on the visit and collected data.
On the same day, the patient will also have an appointment with the PC team (doctor and nurse), as per current protocols at APPI Fibrosi IRCCS AOUBO, during which information on the patient's symptoms, the impact of symptoms on daily life activities, quality of life (QoL), and the patient's support network will be gathered. At the end of the visit, the PC team will express their judgment on the referral of a patient to a specific level of PC, based on the visit and collected data.
As per clinical practice, Pulmonologist B can give their own opinion, but the final decision regarding the assignment is made by the PC team.
The questions administered through the questionnaire were formulated based on elements identified during the clinical practice of pulmonologists and the dedicated nurse of the APPI Fibrosi unit at the IRCCS. These elements are considered most likely to be associated with the need for a higher level of palliative care (PC), namely:
Use of oxygen therapy: This implies the presence of underlying organ failure (respiratory failure) and often constitutes an obstacle for patients leaving their homes, either due to induced depressive and/or anxious states or due to difficulties-especially among elderly patients-in using oxygen therapy devices. IPF is a disease often complicated by the development of chronic partial respiratory failure. Patients are thus at risk of chronic hypoxia and receive long-term home oxygen therapy prescriptions. Although there is no specific literature on adherence to chronic oxygen therapy in IPF patients, it can be assumed to be similar to that observed in patients with other chronic respiratory diseases. In a cohort of patients with chronic obstructive pulmonary disease (COPD), overall adherence to oxygen therapy was 60%, dropping further among those prescribed 24-hour therapy. An Italian study on COPD patients found that only 40% used portable oxygen devices to leave their homes, citing "shame" as the primary limiting factor. Investigators believe that many IPF patients similarly restrict their outings for the same reason.
Progressive exertional dyspnea: This is a common symptom in IPF patients, impacting their quality of life (QoL) over months and years. As the disease progresses, worsening dyspnea makes even minimal physical activities difficult, affecting various aspects of life, including family relationships and social participation. Therefore, investigators have decided to assign a higher score to patients with greater dyspnea levels, as measured by the modified Medical Research Council (mMRC) scale. The mMRC scale is structured as follows:
mMRC 0: Dyspnea with strenuous exertion. mMRC 1: Dyspnea with moderate-to-intense exertion (e.g., brisk walking or running on level ground or slight incline).
mMRC 2: Dyspnea with moderate exertion (e.g., slower walking on level ground compared to peers or needing to stop during normal-paced walking).
mMRC 3: Dyspnea with light exertion (e.g., needing to stop to breathe after walking 100 meters or for a few minutes on level ground).
mMRC 4: Dyspnea at rest (e.g., experiencing dyspnea while dressing or undressing).
Difficulties in reaching the center (APPI Fibrosi) for logistical reasons or lack of caregiver support: Patients with such difficulties are more likely to refuse palliative care at the IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di S. Orsola, which puts them at risk of not receiving adequate support for managing symptoms associated with their underlying condition. On the other hand, home-based or community-based care presents an opportunity for those who would otherwise face challenges in accessing care.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) established after discussion at the Multidisciplinary Interstitial Disease Meeting and referred to the APPI Fibrosi unit of the IRCCS for specialized care
Key inclusion criteria (3 listed)
- Age ≥ 18 years.
- New diagnosis of Idiopathic Pulmonary Fibrosis (IPF) established through a Multidisciplinary Interstitial Disease Meeting.
- Obtaining written informed consent.
Key exclusion criteria (2 listed)
- Patient's inability to understand and/or respond to the questions in the questionnaire as judged by the healthcare provider.
- Patient already receiving care from the Palliative Care Service.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Evaluation of concordance between the levels of palliative care obtained using a triage questionnaire and those derived from the clinical judgments of the dedicated pulmonologist and the dedicated palliative care physician
Time frame: 18 months
The primary objective will be measured by calculating Krippendorff's alpha coefficient of reliability among the classifications obtained with the questionnaire, the clinical judgment of the pulmonologist, and the clinical judgment of the palliative care physician
1 secondary outcome
Description of the degree of palliative care needs that patients with IPF present when referred to the reference pulmonology center
Time frame: 18 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Mar 2026.
- Individual participant dataSharing planned: Undecided
Related trials for IPF
RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
RecruitingObservational study
Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome
Hermansky-Pudlak Syndrome (HPS)
RecruitingPhase 2
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stefano Nava, MD principal investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of IPF, run by IRCCS Azienda Ospedaliero-Universitaria di Bologna at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluation of concordance between the levels of palliative care obtained using a triage questionnaire and those derived from the clinical judgments of the dedicated pulmonologist and the dedicated palliative care physician (time frame: 18 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2026.